Apollo Global Management has agreed to acquire a minority stake in Bayer’s long-acting reversible contraceptives business for €3bn, in a transaction that highlights the private capital firm’s growing role as a provider of large-scale strategic financing to multinational corporations, according to a report by Bloomberg.
The deal gives Apollo an interest in a newly created entity housing Bayer’s contraceptives portfolio, while the German healthcare and agriculture group will retain full operationa...
Continue Reading
Sign up for FREE to read the full article and access 152K+ alternative investment headlines.
Alternative Investment News